{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:42:41Z","timestamp":1782783761131,"version":"3.54.5"},"reference-count":85,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Universal varicella vaccination (UVV) in England and Wales has been hindered by its potential impact on exogenous boosting and increase in herpes zoster (HZ) incidence. We projected the impact of ten UVV strategies in England and Wales on the incidence of varicella and HZ and evaluated their cost-effectiveness over 50 years. The Maternal-Susceptible-Exposed-Infected-Recovered-Vaccinated transmission model was extended in a dynamically changing, age-structured population. Our model estimated that one- or two-dose UVV strategies significantly reduced varicella incidence (70\u201392%), hospitalizations (70\u201390%), and mortality (16\u201341%) over 50 years. A small rise in HZ cases was projected with UVV, peaking 22 years after introduction at 5.3\u20137.1% above pre-UVV rates. Subsequently, HZ incidence steadily decreased, falling 12.2\u201314.1% below pre-UVV rates after 50 years. At a willingness-to-pay threshold of 20,000 GBP\/QALY, each UVV strategy was cost-effective versus no UVV. Frontier analysis showed that one-dose UVV with MMRV-MSD administered at 18 months is the only cost-effective strategy compared to other strategies. HZ incidence varied under alternative exogenous boosting assumptions, but most UVV strategies remained cost-effective. HZ vaccination decreased HZ incidence with minimal impact on the cost-effectiveness. Introducing a UVV program would significantly reduce the clinical burden of varicella and be cost-effective versus no UVV after accounting for the impact on HZ incidence.<\/jats:p>","DOI":"10.3390\/vaccines10091416","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T02:09:36Z","timestamp":1661911776000},"page":"1416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Modeling the Impact of Exogenous Boosting and Universal Varicella Vaccination on the Clinical and Economic Burden of Varicella and Herpes Zoster in a Dynamic Population for England and Wales"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-5670","authenticated-orcid":false,"given":"Oluwaseun","family":"Sharomi","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Xausa","sequence":"additional","affiliation":[{"name":"Wolfram Research Inc., 100 Trade Center Drive, Champaign, IL 61820, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nachbar","sequence":"additional","affiliation":[{"name":"Wolfram Research Inc., 100 Trade Center Drive, Champaign, IL 61820, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Pillsbury","sequence":"additional","affiliation":[{"name":"Independent Researcher, Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-6512","authenticated-orcid":false,"given":"Ian","family":"Matthews","sequence":"additional","affiliation":[{"name":"Merck Sharpe and Dome (UK) Ltd., 120 Moorgate, London EC2M 6UR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaz","family":"Petigara","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-8036","authenticated-orcid":false,"given":"Elamin","family":"Elbasha","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjiri","family":"Pawaskar","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bonanni, P., Breuer, J., Gershon, A., Gershon, M., Hryniewicz, W., Papaevangelou, V., Rentier, B., R\u00fcmke, H., Sadzot-Delvaux, C., and Senterre, J. (2009). Varicella vaccination in Europe\u2013taking the practical approach. BMC Med., 7.","DOI":"10.1186\/1741-7015-7-26"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4161\/hv.7.8.15685","article-title":"Should the chickenpox vaccine be included in the national immunization schedule in India?","volume":"7","author":"Verma","year":"2011","journal-title":"Hum. Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/INF.0b013e31826ff3a5","article-title":"Incidence and use of resources for chickenpox and herpes zoster in Latin America and the Caribbean\u2014A systematic review and meta-analysis","volume":"31","author":"Bardach","year":"2012","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1086\/522163","article-title":"Varicella vaccination in Japan, South Korea, and Europe","volume":"197","author":"Rentier","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","article-title":"Varicella vaccination-the global experience","volume":"16","author":"Wutzler","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1473-3099(18)30716-3","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial","volume":"19","author":"Povey","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","article-title":"Long-term effectiveness of varicella vaccine: A 14-year, prospective cohort study","volume":"131","author":"Baxter","year":"2013","journal-title":"Pediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs","volume":"15","author":"Varela","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","unstructured":"CDC (2021, September 29). Chickenpox, Available online: https:\/\/www.cdc.gov\/chickenpox\/hcp\/index.html."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1016\/j.vaccine.2008.08.016","article-title":"Impact of varicella vaccination on health care outcomes in Ontario, Canada: Effect of a publicly funded program?","volume":"26","author":"Kwong","year":"2008","journal-title":"Vaccine"},{"key":"ref_13","unstructured":"World Health Organization (2014). Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly. Epidemiol. Rec. Relev. \u00c9pid\u00e9miologique Hebd., 89, 265\u2013287."},{"key":"ref_14","unstructured":"(2022, July 28). Green Book Chapter 34, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1056198\/Green_Book_Chapter_34_v3_0.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1017\/S0950268817001649","article-title":"Trends in the burden of varicella in UK general practice","volume":"145","author":"Walker","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/adc.88.10.862","article-title":"Varicella vaccination in England and Wales: Cost-utility analysis","volume":"88","author":"Brisson","year":"2003","journal-title":"Arch. Dis. Child."},{"key":"ref_17","unstructured":"(2022, July 28). Joint Committee on Vaccination and Immunization: Statement on Varicella and Herpes Zoster Vaccines. Available online: https:\/\/www.nitag-resource.org\/sites\/default\/files\/e361266bc0e478ac95c2bcf4bc698b40186f2206_2.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"Melegaro","year":"2012","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"I6987","DOI":"10.1136\/bmj.l6987","article-title":"Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: Self controlled case series study using UK electronic healthcare data","volume":"368","author":"Forbes","year":"2020","journal-title":"BMJ"},{"key":"ref_20","first-page":"995","article-title":"The impact of varicella vaccination on the incidence of varicella and herpes zoster in the United States: Updated evidence from observational databases, 1991\u20132016","volume":"70","author":"Wolfson","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/infdis\/jiy418","article-title":"Point\u2013Counterpoint: The Hope-Simpson Hypothesis and Its Implications Regarding an Effect of Routine Varicella Vaccination on Herpes Zoster Incidence","volume":"218","author":"Harpaz","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wolfson, L.J., Daniels, V.J., Pillsbury, M., Kurug\u00f6l, Z., Yardimci, C., Kyle, J., and Dinleyici, E.C. (2019). Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220921"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/bulm.1999.0126","article-title":"Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles","volume":"61","author":"Schuette","year":"1999","journal-title":"Bull. Math. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1002\/jmv.10317","article-title":"Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV","volume":"70","author":"Brisson","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1017\/S0950268817001546","article-title":"A systematic review of varicella seroprevalence in European countries before universal childhood immunization: Deriving incidence from seroprevalence data","volume":"145","author":"Bollaerts","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1016\/j.vaccine.2007.07.036","article-title":"The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region","volume":"25","author":"Nardone","year":"2007","journal-title":"Vaccine"},{"key":"ref_27","unstructured":"Office for National Statistics (ons.gov.uk) (2022, July 28). Births by Parents\u2019 Characteristics, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/livebirths\/datasets\/birthsbyparentscharacteristics."},{"key":"ref_28","unstructured":"(2022, July 28). National Population Projections\u2014Office for National Statistics, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationprojections\/bulletins\/nationalpopulationprojections\/2018based#toc."},{"key":"ref_29","unstructured":"Office for National Statistics (ons.gov.uk) (2022, July 28). Causes of Death over 100 Years, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/articles\/causesofdeathover100years\/2017-09-18."},{"key":"ref_30","unstructured":"Office for National Statistics (ons.gov.uk) (2022, July 28). National Population Projections, Migration Assumptions: 2018-Based, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationprojections\/methodologies\/nationalpopulationprojectionsmigrationassumptions2018based."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Prem, K., Cook, A.R., and Jit, M. (2017). Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput. Biol., 13.","DOI":"10.1371\/journal.pcbi.1005697"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1542\/peds.58.5.692","article-title":"Antibody to varicella-zoster virus in parturient women and their offspring during the first year of life","volume":"58","author":"Gershon","year":"1976","journal-title":"Pediatrics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1001\/jama.1929.02710260001001","article-title":"The Period of Infectivity and Serum Prevention of Chicken-pox","volume":"93","author":"Gordon","year":"1929","journal-title":"J. Am. Med. Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Heymann, D. (2015). Control of Communicable Diseases Manual: An Official Report of the American Public Health Association, American Public Health Association.","DOI":"10.2105\/CCDM.2745.014"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.1997.03550180045035","article-title":"Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center","volume":"278","author":"Izurieta","year":"1997","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jama.292.6.704","article-title":"Contagiousness of varicella in vaccinated cases: A household contact study","volume":"292","author":"Seward","year":"2004","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1073\/pnas.93.14.7231","article-title":"Mass vaccination to control chickenpox: The influence of zoster","volume":"93","author":"Ferguson","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Poletti, P., Melegaro, A., Ajelli, M., del Fava, E., Guzzetta, G., Faustini, L., Tomba, G.S., Lopalco, P., Rizzo, C., and Merler, S. (2013). Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060732"},{"key":"ref_39","first-page":"1137","article-title":"Herpes zoster in general practice","volume":"16","author":"Trollor","year":"1987","journal-title":"Aust. Fam. Physician"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/aje\/kwj317","article-title":"Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents","volume":"164","author":"Wallinga","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"Melegaro","year":"2011","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.clinthera.2014.12.017","article-title":"The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix","volume":"37","author":"Ouwens","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/j.jval.2020.08.927","article-title":"PIN86 Modeling Performance Parametrization of Varicella Vaccines","volume":"23","author":"Pillsbury","year":"2020","journal-title":"Value Health"},{"key":"ref_44","unstructured":"Joint Committee on Vaccination and Immunisation (2022, April 29). Minute of the Meeting Held on 22 June 2021, Available online: https:\/\/app.box.com\/s\/iddfb4ppwkmtjusir2tc\/file\/849032554320."},{"key":"ref_45","unstructured":"NHS Digital (2022, July 28). Childhood Vaccination Coverage Statistics 2019\u20132020: Data Tables, Available online: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/nhs-immunisation-statistics\/england---2019-20."},{"key":"ref_46","unstructured":"Public Health England (2022, July 28). Td\/IPV School-Based Programme to 31 August 2019: Vaccine Coverage Data Tables, Available online: https:\/\/www.gov.uk\/government\/publications\/school-leaver-booster-tdipv-vaccine-coverage-estimates."},{"key":"ref_47","unstructured":"(2021, October 15). Lauer Fischer. Available online: https:\/\/www.lauer-fischer.de\/LF\/Seiten\/Verwaltung\/Kundencenter\/1.aspx."},{"key":"ref_48","unstructured":"(2022, July 28). Botplus. Available online: https:\/\/botplusweb.portalfarma.com\/botplus.aspx."},{"key":"ref_49","unstructured":"(2022, July 28). Federal Office of Public Health FOPH. Available online: http:\/\/www.xn--spezialittenliste-yqb.ch\/ShowPreparations.aspx."},{"key":"ref_50","unstructured":"(2021, October 15). Varicella Vaccine Zoster. Available online: https:\/\/bnfc.nice.org.uk\/medicinal-forms\/varicella-zoster-vaccine.html."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e3617","DOI":"10.1093\/cid\/ciaa1708","article-title":"Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom","volume":"73","author":"Akpo","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","unstructured":"(2018, October 01). Code of Practice: Joint Committee on Vaccination and Immunisation, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/224864\/JCVI_Code_of_Practice_revision_2013_-_final.pdf."},{"key":"ref_53","unstructured":"Department of Health and Social Care (2021, September 19). Cost-effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP), Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/807856\/CEMIPP_Consultation_Response_1.pdf."},{"key":"ref_54","unstructured":"National Institute for Health and Care Excellence (2021, September 30). Guide to the Methods of Technology Appraisal 2013. Available online: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case#discounting."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.vaccine.2010.02.079","article-title":"Modeling the impact of one-and two-dose varicella vaccination on the epidemiology of varicella and zoster","volume":"28","author":"Brisson","year":"2010","journal-title":"Vaccine"},{"key":"ref_56","unstructured":"Public Health England (2022, May 19). Research and Analysis: Herpes Zoster (Shingles) Immunisation Programme 2013 to 2014: Evaluation Report, Available online: https:\/\/www.gov.uk\/government\/publications\/herpes-zoster-shingles-immunisation-programme-2013-to-2014-evaluation-report."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in Economic Evaluations","volume":"36","author":"Attema","year":"2008","journal-title":"Pharm. Econ."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/j.pain.0000000000000307","article-title":"A systematic review and meta-analysis of risk factors for postherpetic neuralgia","volume":"157","author":"Forbes","year":"2016","journal-title":"Pain"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella zoster virus","volume":"125","author":"Brisson","year":"2000","journal-title":"Epidemiol. Infect."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.clinthera.2015.01.006","article-title":"Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: An economic analysis based on a dynamic transmission model for varicella and herpes zoster","volume":"37","author":"Littlewood","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Melegaro, A., Marziano, V., Del Fava, E., Poletti, P., Tirani, M., Rizzo, C., and Merler, S. (2018). The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: A modelling and cost-effectiveness study. BMC Med., 16.","DOI":"10.1186\/s12916-018-1094-7"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/CEOR.S229685","article-title":"The cost-effectiveness of universal varicella vaccination in Italy: A model-based assessment of vaccination strategies","volume":"12","author":"Azzari","year":"2020","journal-title":"Clin. Econ. Outcomes Res. CEOR"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/21645515.2019.1672491","article-title":"Budget impact analysis of multiple varicella vaccination strategies: A Mexico perspective","volume":"16","author":"Graham","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Pawaskar, M., Burgess, C., Pillsbury, M., Wisl\u00f8ff, T., and Flem, E. (2021). Clinical and economic impact of universal varicella vaccination in Norway: A modeling study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0254080"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/INF.0000000000003136","article-title":"Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland","volume":"40","author":"Heininger","year":"2021","journal-title":"Pediatric Infect. Dis. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14760584.2018.1538801","article-title":"Understanding the role of exogenous boosting in modeling varicella vaccination","volume":"17","author":"Talbird","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1002\/jmv.10313","article-title":"Epidemiology of varicella-zoster virus in England and Wales","volume":"70","author":"Brisson","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1137\/S0036144500371907","article-title":"The mathematics of infectious diseases","volume":"42","author":"Hethcote","year":"2000","journal-title":"Siam Rev."},{"key":"ref_70","first-page":"978","article-title":"The basic approach to age-structured population dynamics","volume":"10","author":"Iannelli","year":"2017","journal-title":"Mod. Meth. Numer."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cam.2005.11.033","article-title":"Numerical methods for the Lotka\u2013McKendrick\u2019s equation","volume":"197","author":"Pelovska","year":"2006","journal-title":"J. Comput. Appl. Math."},{"key":"ref_72","unstructured":"(2022, July 28). Estimates of the population for the UK, England and Wales, Scotland and Northern Ireland\u2013Office for National Statistics (ons.gov.uk) [Internet], Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol. Infect."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268803001523","article-title":"Gender difference in the incidence of shingles","volume":"132","author":"Fleming","year":"2004","journal-title":"Epidemiol. Infect."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","article-title":"The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales","volume":"19","author":"Edmunds","year":"2001","journal-title":"Vaccine."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/jcp.55.2.154","article-title":"Changes in age related seroprevalence of antibody to varicella zoster virus: Impact on vaccine strategy","volume":"55","author":"Kudesia","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0022-3476(97)80019-4","article-title":"Community impact of childhood varicella infections","volume":"130","author":"Yawn","year":"1997","journal-title":"J. Pediatr."},{"key":"ref_78","unstructured":"(2022, July 28). Pre-Primary School Enrollment (Kindergarten, Nursery) for Children Aged 3-5 Years from 1970 to 2016 [Internet]. StatInvestor. Available online: https:\/\/statinvestor.com\/data\/32099\/pre-primary-school-enrollment\/."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"Hobbelen","year":"2016","journal-title":"J. Infect."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Szende, A., Janssen, B., and Cabases, J. (2014). Self-Reported Population Health: An International Perspective based on EQ-5D, Springer. Dordrecht (NL).","DOI":"10.1007\/978-94-007-7596-1"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","article-title":"Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey","volume":"6","author":"Oster","year":"2005","journal-title":"J. Pain."},{"key":"ref_83","unstructured":"(2022, July 28). Office for National Statistics, Available online: https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/datasets\/averageweeklyearningsearn01."},{"key":"ref_84","unstructured":"Public Health England (2022, July 28). Shingles Vaccine Coverage Report (Adults Eligible from April to December 2021 and Vaccinated to the End of March 2022): England, Available online: https:\/\/www.gov.uk\/government\/publications\/herpes-zoster-shingles-immunisation-programme-2021-to-2022-evaluation-reports\/shingles-vaccine-coverage-report-adults-eligible-from-april-to-december-2021-and-vaccinated-to-the-end-of-march-2022-england."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u2265 60 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:19:14Z","timestamp":1760141954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":85,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["vaccines10091416"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10091416","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]}}}